Advance your academic career, collaborate globally, and expand your network— join now !

Emmanuel S. Antonarakis

Dr. Emmanuel S. Antonarakis

Prostate Cancer Research Program, Sidney Kimmel Comprehensive Cancer Center, Joh...

Share Link

Share

Information

Dr. Emmanuel S. Antonarakis is the Clark Endowed Professor of Medicine, and a genitourinary medical oncologist with a particular focus on recurrent and advanced prostate cancer. He conducts clinical and translational studies to bring new therapies to patients with prostate cancer. In particular, he is interested in developing novel androgen-directed therapies, genetically targeted therapies, and immunotherapies for men with recurrent or advanced prostate cancer, and using germline and tumor genomics to inform precision oncology approaches for these patients. He also has an interest in liquid biomarker development, including the clinical validation of the AR-V7 marker as well as DNA repair markers and their therapeutic implications. He is also involved in mentoring fellows and junior faculty in the clinical care of genitourinary cancers and the development of translational research strategies related to prostate cancer.

Research Keywords & Expertise

Immunotherapy
Prostate cancer clinic...
Prostate cancer biomar...
AR-V7 biomarker
Androgen receptor-targ...

Fingerprints

6%
Immunotherapy
5%
Prostate cancer clinical trials
5%
Prostate cancer biomarker development
5%
AR-V7 biomarker
5%
Androgen receptor-targeted therapy

Short Biography

Dr. Emmanuel S. Antonarakis is the Clark Endowed Professor of Medicine, and a genitourinary medical oncologist with a particular focus on recurrent and advanced prostate cancer. He conducts clinical and translational studies to bring new therapies to patients with prostate cancer. In particular, he is interested in developing novel androgen-directed therapies, genetically targeted therapies, and immunotherapies for men with recurrent or advanced prostate cancer, and using germline and tumor genomics to inform precision oncology approaches for these patients. He also has an interest in liquid biomarker development, including the clinical validation of the AR-V7 marker as well as DNA repair markers and their therapeutic implications. He is also involved in mentoring fellows and junior faculty in the clinical care of genitourinary cancers and the development of translational research strategies related to prostate cancer.